5168
The Oral Apelin Receptor Agonist Azelaprag Enhances Glycemic Control in Preclinical Models of Diabetic Obesity Both as Monotherapy and in Combination with Tirzepatide
Date
June 21, 2025
Explore related products in the following collection:
Speaker
BioAge Labs
